Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
Sign Up to like & getrecommendations! Published in 2021 at "Targeted Oncology"
DOI: 10.1007/s11523-021-00829-y
Abstract: Patients with metastatic renal cell carcinoma (mRCC) are often elderly and have various comorbidities, including cardiovascular diseases. Although these patients have extensive co-exposure to targeted therapy and cardiovascular drugs, the impact of this co-exposure on… read more here.
Keywords: renal cell; pazopanib first; cell carcinoma; sunitinib pazopanib ... See more keywords
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of geriatric oncology"
DOI: 10.1016/j.jgo.2020.09.009
Abstract: BACKGROUND There is poor data on the prognostic role of Comprehensive Geriatric Assessment (CGA) in older patients with metastatic renal cell carcinoma (mRCC) treated with first line Tyrosine Kinase Inhibitors (TKIs). MATERIALS AND METHODS We… read more here.
Keywords: first line; vulnerable frail; sunitinib pazopanib; line ... See more keywords
Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.14185
Abstract: Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in… read more here.
Keywords: imatinib sunitinib; sunitinib pazopanib; pazopanib flat; fixed dosing ... See more keywords
Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.475
Abstract: 475Background: Evidence on economic outcomes could provide insight on comparative economic benefit of TTs. This study assessed all-cause healthcare resource utilization (HRU) and costs among aRCC patients who initiated pazopanib and sunitinib, two commonly-used first… read more here.
Keywords: pazopanib first; medicare data; sunitinib pazopanib; initiated sunitinib ... See more keywords
Effects of sunitinib and pazopanib on patients physical, social, and emotional function: Result of a prospective patients reported outcome tool.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.667
Abstract: 667 Background: Sunitinib and pazopanib are are effective treatment options for metastatic Renal cell carcinoma (mRCC) and both may impair patient’s quality of life (QOL). There has been no direct comparison between these agents and… read more here.
Keywords: pazopanib patients; patients physical; outcome tool; reported outcome ... See more keywords